On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwanﾒs Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization against SARS-CoV-2 in individuals aged 18 and over.